Home / Transcripts / Perrigo Company plc (PRGO) · May 6, 2026

Perrigo Company plc (PRGO) Earnings Call Transcript

May 6, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 49 min

Earnings Call Speaker Segments

Eric Jacobson executive
#1

Good morning, and good afternoon to all of you joining us. Welcome to Perrigo's conference call covering first quarter 2026 earnings. The release that went out earlier today, plus the slide deck for our discussion, are available on the Investors page at perrigo.com. Joining us are Patrick Lockwood-Taylor, our President and CEO, and Eduardo Bezerra, our CFO. One note before we begin: as of this quarter, our reportable segments now align with the new commercial operating model we've adopted. Historical figures have been restated to reflect that structure so comparisons hold, and you can find that in our 8-K filing. Our consolidated financials and cash flows were unaffected by this change. Beyond the introduction of new reporting segments, our primary profitability metric has been changed to adjusted operating income. Certain forward-looking statements are going to be made by participants during this presentation. Information about these statements, which carry significant risks and uncertainties, can be found in the slides; non-GAAP adjusted financial measures will be referenced by us. Additional details, along with reconciliations of every non-GAAP to GAAP financial measure presented, appear in the appendix of the earnings presentation. And lastly, only non-GAAP financial measures will be covered in Patrick's discussion. Turning now to the agenda. Today there are a number of topics for us to address. To start, the progress being made with our Three-S plan, and how first quarter results stack up against our expectations, will be discussed by Patrick. Next, he'll walk everyone through the market landscape and lay out why our growth efforts should translate into better performance. Following that, Eduardo will walk through the segment results for the first quarter, along with the balance sheet and how we're allocating capital, then wrap up by sharing more specifics on what we expect for 2026. On that note, I'll hand things over to Patrick.

Patrick Lockwood-Taylor executive
#2

Thanks, Eric. Good morning, good afternoon, and I appreciate you all being on today's call. We're making consistent headway in shaping a Perrigo that is more focused, more disciplined, and more consistent. The first quarter's results took a hit from a difficult market backdrop. Even so, our Three-S plan — stabilize, streamline, and strengthen — is helping us steer through these circumstances and putting the company in position for growth over the long term. That strategy is delivering, as our share gains make plain, even during what we've described as a transition year. On the strength of all this, we're reaffirming our 2026 outlook. Like we mentioned earlier, the outcome ought to lean toward the back half of the year, and there are tangible, measurable reasons behind that: category consumption is settling down, we're moving past the manufacturing volume challenges we faced a year ago, our cost-reduction programs are paying off, and we're carrying out the initiatives meant to drive growth. Now that I've set that groundwork, I'd like to walk you through the ways the Three-S plan is delivering real improvement. Thanks to our stabilization efforts, what had been share declines in U.S. store brand OTC have turned around, becoming a volume share increase of 100 basis points during the quarter, and six out of seven categories gained share. To put that result in fuller perspective, during the first quarter alone we picked up 270 basis points of U.S. store brand OTC volume share. In Europe, our key brands likewise improved, gaining 20 basis points in value share even as consumers held back. Improved service levels and more dependable supply have helped us stabilize Infant Formula results as well. Turning to business simplification: in April we completed the sale of the Dermacosmetics business — an important milestone that makes our operations simpler still and opens the way to paying down debt. Reviews of strategic options for Infant Formula and Oral Care are ongoing. Our streamlined pillar places great weight on efficiencies, and this quarter our operational enhancement program generated more than $7 million in cost savings, which keeps us on pace for about $60 million to $80 million in savings this year, plus a further $20 million to $40 million expected in 2027. We've made changes to bolster the company, including adopting an operating model organized around categories and enhancing the leadership in our commercial and category teams by recruiting experienced individuals whose skills and viewpoints align with what Perrigo needs for its next stage of growth. These adjustments amount to a major transformation in how we function. By aligning our decision-making, where we invest, and our performance targets under the new structure, we can more effectively leverage a key competitive edge: our size. Perrigo is well-situated to take a leading role in this area, given our portfolio of more than 250 molecules, solid relationships with retailers, a dependable supply chain, and extensive regulatory knowledge. Additionally, the new structure focuses our investments on a smaller set of larger brands, targeting categories with faster growth where our competitive position is strongest. These changes are paying off, as our strong market share performance shows. That said, many benefits from these initiatives aren't fully realized yet and are somewhat hidden by the headwinds we expect to ease in the year's second half. Within that set of challenges, we have milder occurrences of cough and cold, plus retailers pulling back on inventory. Those factors, together with a $0.26 EPS drag tied to the carryover of manufacturing volume headwinds from the prior year, pressed down on our first quarter performance. As we said last quarter, the manufacturing volume headwinds from the prior year should produce an unfavorable All In EPS effect of roughly $0.60 in 2026. To repeat what we've said, these challenges seem largely temporary, so 2026 will be a year of transition in its own right. When conditions change, following our Three-S plan, we're focused on driving better results in the areas we can influence—streamlining how we spend while accelerating revenue growth. Given that, let's examine what underpins our belief that 2026 is a transition year, one that largely played out the way we anticipated in Q1. As we began the year, our assumption was that softness in the market would carry through the first six months and then shift to quarter-over-quarter gains in the back half. In Q1, however, a milder season for cough and cold, combined with macroeconomic strain—particularly in Europe—drove consumption below our forecast. We put the drag from that light cough and cold season at roughly 3.5% on CORE sales. In response to softer consumption, U.S. and European retailers reduced their inventory positions, which weighed on sales even more and added another 3 points of CORE sales headwind. Even so—echoing what others across the industry have said—we continue to anticipate demand strengthening on a sequential basis, driven by a more stable seasonal pattern for cough and cold. We also anticipate that, as consumption improves, retailer inventory levels will move in a favorable direction over time. The second thing we assumed was that we could extend the substantial market share gains achieved in 2025. That assumption held up, as we delivered strong market share results across both store brand and branded products. Fourth—sorry, third—we anticipated that net sales would grow via four main revenue drivers: innovation centered on consumers, expansion into targeted geographies, additional distribution gains and stronger demand generation. During the first quarter we advanced in all of these areas, which reinforces our confidence in an improvement during the second half. Turning now to our financial results. The first quarter shows softness in the category, which was partly offset by the progress we made executing the Three-S plan. CORE net sales came in down 8.3%, and the main reason was weaker consumption in the Self Care segment, tied to fewer cough and cold cases as well as retailers pulling back on inventory. Those factors made up close to two-thirds of the drop in net sales. Partly making up for that were gains driven by share in the Specialty Care segment, especially within women's health. All In net sales fell 7.2 points, showing similar pressures, though better Infant Formula performance offered some offset. Adjusted CORE EPS reached $0.40, held back by manufacturing volume headwinds from the prior year and reduced net sales volumes, mostly in our Self Care segment. Our adjusted EPS beat what we had projected, helped by net recognition of recovering some tariffs we'd paid before, a reduced effective tax rate, and gains from our operational enhancement program. All In adjusted EPS for the quarter landed at $0.43. Let's now examine market performance. The first quarter delivered tough conditions, just as we expected. In the U.S., OTC market value declined 4.1 points while volume dropped 2.1 points, closely matching the fourth quarter's pattern. In Europe, conditions deteriorated further, with value down 3.7% and volume down 4.4%. What's driving these trends in both the U.S. The main issue in Europe is softer demand from consumers in the cough, cold, and pain areas, all of which belong to the Self Care segment. This weakness appears to be short-lived, driven largely by difficult prior-year comparisons, lower-than-normal illness incidence, and macroeconomic pressure, particularly in Europe. As comparisons become easier and more typical seasonal trends return during the second half of 2026, we expect the category to stabilize over the year. To offset these category challenges, we are focusing on the factors within our control. As I said earlier, in the U.S., Perrigo gained volume share in six out of seven OTC categories, and our store brand portfolio extended its run to 12 consecutive periods of share growth. Over in Europe, the brands we're prioritizing picked up value share, and that was driven by really solid performance from ellaOne, which gained 200 basis points, Jungle Formula, which climbed 140 basis points, and Physiomer, which added 50 basis points.

Patrick Lockwood-Taylor executive
#3

Additional strong performers were Mederma Cold Sore and Opill, which rose 180 basis points and 40 basis points, respectively. What's key is that with summer arriving, we're seeing momentum build for our seasonal brands in a number of important European markets. Compeed is gaining strength as it heads into peak season, posting impressive share gains and sellout trends, helped by earlier activation and great in-store execution; in Italy, for instance, Compeed's market share climbed 550 basis points to 35%. Meanwhile, in France it's outpacing the category by a wide margin, with Compeed gaining 160 basis points and our share nearing 36%. Focused investment, better activation, and stronger retailer execution drove this; and that strong performance gives us confidence in our capacity to deliver growth as demand builds over the summer. With category demand normalizing, we expect the greater earnings power that this brand strength enables to become more and more apparent. As we've said, we're generating share gains by scaling our CORE capabilities consistently throughout the portfolio. Nicotine replacement therapy is a great example of how we approach 360-degree innovation. Our process now creates claims, formulations and regulatory platforms once at the category level, and then rolls them out holistically across national brands and store brands spanning formats, geographies and price points. Crucially, this innovation widens the addressable market past traditional quitters to encompass vapers and dual users, which lets us scale faster and unlock incremental demand without introducing complexity. Store brand demand generation is another scalable differentiator for Perrigo. No other large-scale store brand supplier besides us delivers national brand demand generation capabilities to retailers, which lets us partner with retailers and lift conversations above merely the procurement price. Retailers feel attracted to this program since it builds awareness for their business, it strengthens the perception of quality and equivalents, it boosts household penetration and improved retailer profits. Retailers, and an increasing number of them, are requesting that we extend these programs into even more OTC categories. Demand generation packs a big impact for Perrigo. When we pair it with solid retail execution, we achieve better competitive takeaway and share gains. And such gains can be significant, since a 1 point rise in U.S. store brand household penetration equals incremental sales exceeding $100 million of store brand OTC at retail. Targeted geographic expansion lets us carry our existing successful initiatives into new areas. By selectively bringing priority brands into new markets, we can generate incremental growth at lower risk, secure faster payback and higher returns. Keep in mind, this represents a long growth runway for Perrigo, since right now we serve only about 5% of global households. Taken together, these capabilities create a repeatable and scalable growth model. 360-degree innovation widens our opportunity set. Store brand demand generation turns that opportunity into sustained consumption, and targeted geographic expansion magnifies the impact, enabling us to scale performance across categories and regions. What we're seeing here is the translation of that into early yet meaningful gains within the market. This is truly the result that we've been aiming at for 3 years now — Perrigo's sustainable growth model, one built on a portfolio with sharper focus that does a better job of capitalizing on our core strengths and on our unique asset base, all of it supported by a commercial operating model that is far more effective. To sum up, the first quarter's results speak to a market that is very challenging, yet they also show how well our strategy is working. Looking ahead, our attention is on creating a business that is more focused, more disciplined and more consistent. Through carrying out our Three-S plan, we anticipate offsetting the challenges currently facing our categories while also driving growth over the long term. Our full year 2026 guidance is being reaffirmed, and we anticipate it will be weighted toward the second half. That phasing has the backing of clear, quantifiable factors that are already in motion. Our strategy is delivering. Market share gains are showing up. We've got a portfolio with more focus now; our commercial model is more effective and more scalable. I'm aware that quarter 1 revenue and adjusted EPS are being pushed by outside factors that will require careful management. I'll hand things over now to Eduardo, who will take you through the financials in greater detail.

Eduardo Bezerra executive
#4

Thanks, Patrick, and I’m glad everyone could join us today. Before I walk through the details of our first-quarter financial performance, I want to update you on the goodwill impairment. In last quarter’s discussion, we pointed out that reallocating goodwill following our move to new reporting units would probably result in another noncash impairment in the first quarter of 2026. That is precisely what occurred: we recorded a noncash goodwill impairment charge of $331 million, based on the goodwill impairment test we performed as of January 1, 2026, which used the same underlying aggregate fair value of the business that was relied on in the 2025 year-end goodwill test. This charge has no effect on cash flows, liquidity, or our ability to execute the strategy. Unless I say otherwise, everything I discuss from this point will refer to adjusted non-GAAP results. As Eric noted, beginning with this quarter we are reporting segments that align with our new commercial operating model, and those new reporting segments are Self Care, Specialty Care, and Infant Formula. Let’s turn to our results, starting at the top line. CORE net sales declined 8.3% compared with a year ago, under pressure from softer consumption, primarily in cough and cold, along with retailer inventory destocking in the Self Care segment. Stronger Specialty Care net sales partially offset that weakness, driven by our women’s health category; CORE net sales were down 11% on an organic basis. All In net sales were down 7.2%, reflecting the same factors weighing on CORE results plus modest contributions from the Infant Formula and Dermacosmetics business. Currency translation benefited both CORE and All In net sales during the quarter. Now to adjusted operating income by segment: Self Care represented the largest portion of the decline, due to lower net sales volumes, the carryover effect of prior year manufacturing volume headwinds, and unfavorable mix. Partly offsetting those factors were the net recognition of recovery of a portion of previously paid tariffs and favorable currency translation. Specialty Care benefited from lapping prior year Opill investments as well as favorable foreign currency, which more than offset the carryover effect of prior year manufacturing volume headwinds. All In adjusted operating income was mainly shaped by the same factors as CORE, plus an $18 million impact from Infant Formula tied to the carryover of prior year manufacturing volume headwind; operating income growth in all other segments partly offset these impacts. Moving on to margins. The drivers behind both CORE and All In margin changes matched the segment results I just covered. CORE adjusted gross margin fell 160 basis points to 39.2%, mostly from lower sales volumes, manufacturing volume headwinds, and mix. The net recognition of tariff recovery and favorable foreign exchange partly offset these pressures. All In adjusted gross margin fell 340 basis points to 37.6% from the same factors hitting CORE gross margin, plus the Infant Formula manufacturing volume headwinds I just referenced. CORE adjusted operating margin fell 110 basis points, landing at 12.8%. First quarter core adjusted earnings per share was $0.04. That shows the gross margin flow-through, partially counterbalanced by lower advertising and promotion spend, savings from the operational improvement initiative we described to you in Q4, plus a helpful foreign exchange effect. All In adjusted operating margin declined 240 basis points, landing at 11.6%, pushed down by the same items weighing on CORE operating margin as well as the impact from Infant Formula. CORE adjusted earnings per share for the first quarter was $0.40, ahead of our expectations, largely due to net recognition associated with recouping part of the tariffs we had paid earlier, together with a reduced effective tax rate. First quarter core adjusted earnings per share was $0.04. All In adjusted diluted earnings per share declined $0.17 to $0.43, reflecting lower sales volumes and the carryover impact of prior year manufacturing volumes in U.S. OTC and Infant Formula. Turning now to cash flow. Cash from operating activities in the first quarter of 2026 was down $49 million, finishing at an outflow of $114 million, because of softer earnings and greater working capital, in line with our expectations. Remember that the first quarter tends to be when we consume the most cash during the year. Capital expenditures totaled $14 million, and we returned $40 million to shareholders through dividends. Shifting to the balance sheet. Cash and cash equivalents were $357 million, and total debt came to $3.6 billion. During the quarter, we amended our $1 billion revolving credit facility, extending its maturity to 2031. We tapped the revolver to repay our $421 million Term Loan A, which lengthens our maturity schedule so that no major maturities are due until 2029. Looking ahead, we plan to continue actively managing and optimizing our debt maturity profile. After the quarter closed, we completed the divestiture of our Dermacosmetics business for upfront cash proceeds of approximately EUR 306 million, which we intend to direct toward debt reduction. Our priority remains disciplined capital allocation, balancing growth investments, deleveraging and shareholder returns. As we look ahead, although category dynamics were softer than anticipated in the first quarter, our guidance reflects a wide range of possible outcomes and gives us confidence to reaffirm our 2026 outlook. We are closely monitoring retailer inventory movements, particularly the destocking we observed in the first quarter, which we believe is largely linked to the present consumption environment. When consumption improves, we expect inventory patterns to normalize; we are also actively managing the inflationary pressures arising from geopolitical developments in the Middle East and their effect on consumers and our cost base. To counter the estimated incremental in-year impact of $10 million on our cost base, we have implemented sourcing and cost management initiatives, and we will also weigh pricing actions. Like Patrick said, we continue to anticipate that results will skew toward the latter portion of the year, with approximately 30% to 35% of CORE adjusted earnings per share coming in the first half and 65% to 70% arriving in the second half of 2026; this cadence is supported by distinct, measurable drivers, the bulk of which sit in the back half. Turning to 2026, consumer-focused innovation ought to be the largest contributor to sales growth. We anticipate that about 60% of the innovation benefit will materialize in the back half, and that encompasses expanding the Compeed line together with launching new Infant Formula products. Several of our other 2026 drivers should likewise be weighted toward the back half — including distribution gains strengthened by demand generation efforts with major retailers, expansion into targeted geographies, and benefits from our operational enhancement program. Beyond that, we expect interest expense to decline in the second half as we apply the Dermacosmetics proceeds to debt reduction. Alongside those drivers, two of the largest first half headwinds — the carryover impact of last year's manufacturing volume pressures and a milder cough and cold season — are transitory and should lap in the back half. First quarter core adjusted earnings per share was $0.04. As we noted last quarter, last year's manufacturing volume pressures are expected to generate an unfavorable all-in earnings per share impact of roughly $0.60 EPS in 2026. We experienced approximately $0.26 of that impact during the first quarter; in essence, our outlook depends on clear drivers that underpin our second half expectations, many of which are already underway, even as we acknowledge the dynamic macro environment. As Patrick outlined, the Three-S plan is producing tangible improvements, and we're confident we are positioning Perrigo to deliver sustained growth in shareholder value over time. With that, I'll return the call to Eric.

Eric Jacobson executive
#5

Thank you, operator. We're now ready for questions.

Ethan Brown analyst
#6

This is Ethan filling in for Chris Schott. To kick things off — and you did mention this earlier on the call — when we consider how the operating margin for the CORE, basically the non-Infant Formula business, recovers across the back half of this year and on into 2027, could you help set a baseline for how much comes from moving past that pricier inventory in the near term, and how much instead depends on OTC volumes bouncing back and normalizing? Then my second question: any news you can give us regarding the Infant Formula strategic review, plus your latest thinking on timing overall?

Eduardo Bezerra executive
#7

Eduardo speaking. Thanks for the question. As we pointed out, our operating margin in Q1, and then as we gave guidance for the first half of the year, would take a big hit from the carryover volume variance hitting this first half. Beyond that, in the second half we anticipate a substantial pickup in the market — that is, regarding consumption recovery, which we are monitoring very closely given certain dynamics at play. So we anticipate margin gains stemming from the various initiatives we have underway. That means innovation, the continued distribution gains we're achieving, plus stronger demand generation and the opportunistic geographic expansion, along with the ramp-up of the operational enhancement program, which will help our OpEx and operating margin. So on the whole, when we consider how things will look from the first half to the second half, we will see a very meaningful improvement in operating margin expansion thanks to these various factors. On your second question about Infant Formula — right? Just to offer a bit of context, right? The business, as we saw today, delivered a very — relatively good performance this quarter, with net sales up roughly 2%, driven by higher contract manufacturing, while store brand and branded formula were somewhat affected by prior year comparisons, right? So from a market perspective, consumption in store brands is improving slightly relative to what we saw previously. So the first thing regarding your specific question: we are monitoring the business. And remember, we anticipated margins would be significantly impacted by the carryover of manufacturing variances. As for the overall strategic review we are conducting and that we began, the review is ongoing; we're working alongside our advisers to evaluate all available options we discussed earlier, including optimizing our network. Toward that end, we recently announced a rationalization of capacity at one of our facilities, which will help streamline the business and lower our costs. In addition, we're examining other options regarding partnership and divestments. There's nothing further to share at this stage, and we're continuing with that, and we expect to provide additional updates as we move through the year.

Susan Anderson analyst
#8

It's encouraging to see the store brand picking up volume share here in the U.S. Could you perhaps shed some light on what's behind that gain? What are you approaching differently with retailers compared to how you operated previously? And also, I believe you mentioned it spans most categories, but could you specify which categories across the portfolio are showing those gains?

Patrick Lockwood-Taylor executive
#9

Susan, Patrick here. What's behind those share gains? We're securing more contracts. As you're aware, in 2025, that was roughly $100 million in net contract wins. A number of those are being rolled out at present. So we're capturing a bigger portion of store brand contract volume. That's the first thing. Second, beyond simply wanting a bigger portion, we aim to expand store brand's share within the total category; this is essentially where we begin generating equivalents and the value proposition with end consumers, honestly, by deploying brand-building marketing capability that we use on our national brands. That boosts consumer awareness and increases household penetration for store brand. Two things are essential. You want a bigger portion of store brand and you want store brand to hold a bigger share of the marketplace. That gives us a double win; so that's genuinely what's expanding. Regarding — I believe I grasped your question about which categories are expanding. We compete across seven OTC categories; and I think in the presentation deck, we actually laid out which ones are growing. And I think — so we're increasing share in every one of them except skin, where a temporary supply disruption occurred, though it's quite a small business for us. The others, which are the major categories, we're expanding our share of store brands. So allergy is up 180 basis points, pain 110 basis points, digestive health is up 30 basis points, and arguably the standout performance is in nicotine replacement therapy. And I heard a competitor reference this, where we're actually seeing a 540-point volume share growth this calendar year-to-date. So it's broad-based and it's substantial.

Susan Anderson analyst
#10

Okay. That's great, and it does sound good. So next, perhaps you could discuss your preparations for the cold/cough category during the latter half of the year. Should we anticipate that it will at last get back to growth, especially since we are, in a sense, up against some simpler comparisons from the prior calendar year? Or do you lean toward thinking it will be more or less flat? Then, my last question, I suppose, is whether you are considering any pricing actions for the back half of the year, particularly given that we may be observing some additional inflationary pressures at this point?

Patrick Lockwood-Taylor executive
#11

Thank you. Regarding cough/cold, for 25 years I have attempted to forecast cough/cold season, and I am incorrect just as often as I am correct. This cough/cold season was unusually weak, in the U.S. as well as numerous countries across Europe, and so, on the whole. The sensible projection is invariably to assume a typical season. Should we assume a typical season for '26, '27, that will be considerably stronger than the season we have just come through. To me, that is a completely reasonable view and projection. And what was the second part of your question?

Susan Anderson analyst
#12

Turning to pricing, I suppose, yeah.

Patrick Lockwood-Taylor executive
#13

On pricing — well, to begin with, the inflation-related strain coming out of the Middle East has been quite mild in our case, and we'll simply handle that via the usual course of business. That said, we're beginning to examine pricing based on how other commodity costs, and so forth, develop. So yeah, I'd say we're actively weighing that, in both the international branded operation and our store brand operation, in each of the two regions, yes.

Eduardo Bezerra executive
#14

I'd add one more thing to what you said, Susan — something I see as really key. When inflation hits and so on, one area we'll be monitoring carefully is whether store-brand purchases start gaining momentum. That's been up and down in recent years, largely, I'd say, because household finances have stayed solid. It's really only low-income shoppers who've been hit hardest. Typically, that group is the one whose behavior tracks store brands most directly. Should pressure there grow, though, the shift to cheaper options might speed up. If that scenario unfolds, it's a chance for us, and we're positioned to capitalize on it.

Keith Devas analyst
#15

Perhaps we could pull back for a moment and revisit the broader environment where it concerns consumer health. I realize you flagged certain expectations that the back half would improve. I'm simply hoping you might give us additional detail about what exactly is fueling that. It seems to us that both branded and store brand consumption are trending weaker than expected, and for a longer stretch than we had assumed. So I basically want to dig into what assumptions sit behind your view that the back half gets better. Is it perhaps improved clarity around contract awards, or destocking letting up? Simply unpacking that a bit, I believe, would be useful.

Eduardo Bezerra executive
#16

Sure. Appreciate it, Keith; so keep in mind, as we pointed out alongside our guidance, correct, so it bakes in a broad spectrum of possible results there. So when we examine that element, so we have four main areas where we're generating a great deal of consumption opportunities. So on the innovation front, correct? So we touched briefly on the Compeed portfolio and also regarding Infant Formula, launching new products, among them one aimed heavily at the leading competitor in the market today featuring an organic formulation. Ongoing distribution gains. So we keep concentrating heavily on that within the marketplace, with additional competitive take rate, plus demand generation, correct? So recall, we discussed a year ago a few of the illustrations such as what we accomplished with the Lifix in cough and cold and allergy. So we're witnessing an increasing number of retailers eager to expand that throughout their portfolio. And so we think that represents a solid chance to draw in additional consumers to our particular categories within store brand, along with geographic expansion for our priority brands, correct? Yet once more, we recognize the latest developments, correct? So we recognize certain retailer destocking that occurred during the first quarter. We think that is largely tied to the weak cough and cold, with them wanting to be more pragmatic about handling their cash in that regard and modified their inventory levels, though that's something requiring close monitoring; and the other matter too is the degree to which the Middle East geopolitical situation might further develop into inflation and how that could affect consumption during the back half. So we continue to think a recovery will come since the prior year comparison was a major decline, yet we're tracking that carefully. I'm not sure, Patrick, whether there's anything you'd like to add too?

Patrick Lockwood-Taylor executive
#17

Yeah, I believe that's correct. Essentially, we haven't seen any major movement in incidence rates from one category to another. Our household penetration remains pretty steady — for us, that's one narrow segment within a pain area — though what we do see is consumers shifting toward different formats in pain, going from solid pills to creams, and so on. So there's been no drastic alteration when it comes to incidence or household penetration. On top of that, as we walked through, those effects from last year first showed up in quarter 2. That means we'll be anniversarying the onset of that category decline very shortly. As a result, purely based on the arithmetic, it simply levels out on its own. We haven't identified any significant value extraction that appears set to persist through the rest of the year; so once more, the key takeaway is that this will remain a fairly unpredictable range during this year; that's why we built our guidance around a wide spread of possible outcomes. You've already seen what our sales guidance looks like for the year. And you heard during the prior quarter just how heavily our demand generation efforts and cost reduction efforts are weighted toward the back half. That gives our outlook some insulation; so as things stand right now, we're reaffirming our '26 guidance with confidence.

Daniel Biolsi analyst
#18

I'd like to hear your thoughts on how shoppers behave in physical stores compared with on the web when it comes to branded items versus retailer-owned labels in Self Care segments. Would you say there's a fairly clear distinction when it comes to your biggest accounts? Are those accounts effectively surfacing their own private-label options when people run searches? When I check the biggest retailers myself, the experiences vary a lot — searching Advil against ibuprofen, for instance, gives very different results.

Patrick Lockwood-Taylor executive
#19

That's a fair question. Interestingly, e-commerce is actually where a number of our stronger positions in store brand tend to sit. My sense is that, taken together, we could all improve how store brands show up online alongside several of our major legacy retail partners — not just landing pages, which you mentioned, but in certain ad placements too. They purchase the equivalent product, as you're aware, and the value can be considerably better at a moment when a growing number of shoppers are hunting for value. That execution has room to improve. So yes — the established e-commerce operators who are performing — executing more effectively, they capture larger shares, and within that same channel we're genuinely watching growing competitive losses too.

Eduardo Bezerra executive
#20

Right, Daniel, and let me offer a key illustration involving women's health and Opill. During Q1, our e-commerce business expanded by close to 30%, so that's one space where things are going extremely well. Uptake has been quite strong, and meanwhile Opill's sales posted a double-digit increase of 12%. That shows you the significant share of that growth that e-commerce is capturing.

Daniel Biolsi analyst
#21

Also, what is the Board currently thinking regarding the dividend?

Eduardo Bezerra executive
#22

Pardon me, would you say that again?

Patrick Lockwood-Taylor executive
#23

The dividend from the Board.

Eduardo Bezerra executive
#24

Right. So, just like we discussed during the previous quarter, we're staying the course on our capital allocation strategy, correct — we'll keep putting money into our core business, plus we're placing a lot of emphasis on bringing debt down as well, while maintaining returns for our shareholders, right? That same focus is what we'll carry forward. And on a quarterly basis, the Board is going to keep evaluating things — where do we stand so we can make sure our capital allocation is optimized — and they chose to maintain that, and for the rest of the year, those conversations are going to keep happening.

Patrick Lockwood-Taylor executive
#25

I appreciate it greatly. And once more, my thanks to all of you for being here. So in wrapping up, let me frame this quarter clearly. The efforts put in across the last several years are producing real change at Perrigo. Ours is now a business that is more focused, more disciplined, and more consistent, and that sturdier base lets us navigate a tough environment better than would have been possible before. What we pledged, we are delivering; the Dermacosmetics divestiture is done, and those proceeds are going toward lowering debt. Our cost-saving initiative is running at or slightly better than what we expected. The portfolio is being simplified. Operations are getting stronger, with Infant Formula continuing to make progress. Simultaneously, we're gaining substantial share, which confirms our commercial strategy is succeeding. Still, the quarter wasn't flawless. Weaker cough and cold demand, inventory destocking, and consumption pressure in Europe held back results; yet crucially, better operating capabilities let us offset that pressure and seize opportunities as they appeared, shown by the fact that EPS and our share gains both beat what we expected. Now that we're in the second quarter, the ongoing momentum in market share and in-market execution we see throughout the portfolio is likewise encouraging. That progress builds our confidence as the year unfolds and strengthens our belief in the 2026 outlook and the long-term path. Disciplined execution stays our focus, along with controlling whatever we can and creating lasting value over time. Many thanks for your continued interest and support.

Operator operator
#26

Appreciate it, everyone. That wraps up the call for today. Thanks for joining us, and you're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Perrigo Company plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Perrigo Company plc earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.